Abstract
Expression of E- and P-selectin ligands is required for T cell entry into skin. Sialyl Lewis X moieties are critical for ligand activity and are elevated on malignant skin-homing T cells. We hypothesize that these glycosylations are selectable targets for treating the dermal tropism associated with cutaneous lymphomas. In this study, we analyzed the efficacy of a novel 4-fluorinated analog of N-acetylglucosamine (GlcNAc) on E- and P-selectin ligands expressed by malignant skin-homing T cells. We also examined the specificity of 4-F-GlcNAc (2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose) action by contrasting the effects on sialyl Lewis X expression displayed by P-selectin glycoprotein ligand-1 (PSGL-1) with sialylated O-glycans expressed by CD43. Using parallel-plate flow analysis, we found that 4-F-GlcNAc elicited 5-fold more potent inhibition on P-selectin ligand activity than on E-selectin ligand activity. To determine whether glycosylations conferring E- and P-selectin ligand activities were inhibited, we analyzed the expression of sialyl Lewis X and sialyl-fucosylated core 2 O-glycan (CHO-131 antigen), respectively. We found that 4-F-GlcNAc treatment resulted in dose-dependent ablation of sialyl Lewis X and CHO-131 antigen expression on PSGL-1, whereas sialylated O-glycans on CD43 were minimally affected. These results indicate that 4-F-GlcNAc treatment can selectively downregulate the P-selectin ligand activity and potentially prevent dermal dissemination of cutaneous lymphomas.
Original language | English (US) |
---|---|
Pages (from-to) | 2065-2073 |
Number of pages | 9 |
Journal | Journal of Investigative Dermatology |
Volume | 126 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2006 |
Bibliographical note
Funding Information:We thank Dr Ralph Bernacki (Roswell Park Cancer Institute, Buffalo, NY) for providing 4-F-GlcNAc, and Natalia Trujillo and Darcy Brown for their technical assistance in preliminary experiments. This work was supported by NIH/NCI Grants, 1R21 CA102913-03 (C.J. Dimitroff) and 1R21 CA104828-02 (C.J. Dimitroff), and by NIH/NIAMS Grants, 5P30AR042689-12 and R21AR49333 (B. Walcheck).